We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition PR Newswire Reykjavik, ICELAND, Nov. 6, 2023 Reykjavik, ICELAND, Nov. 6, 2023 /PRNewswire/ -- A...
D E Shaw & Co LP 06 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022...
Geode Capital Management LLC 05 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER...
D E Shaw & Co LP 05 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022...
Geode Capital Management LLC 04 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER...
D E Shaw & Co LP 04 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022...
Major drugmakers have grudgingly agreed to negotiate on reducing prices for 10 medicines, the White House said Tuesda ...
Geode Capital Management LLC 03 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER...
D E Shaw & Co LP 03 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022...
Geode Capital Management LLC 02 October 2023 Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -5.25 | -1.93014705882 | 272 | 272 | 259 | 4815 | 266.17998505 | DE |
4 | -25.75 | -8.80341880342 | 292.5 | 295.5 | 259 | 5481 | 273.47913797 | DE |
12 | -59 | -18.1120491174 | 325.75 | 328 | 259 | 8928 | 310.44839976 | DE |
26 | -39.25 | -12.8267973856 | 306 | 339 | 259 | 7280 | 318.15699372 | DE |
52 | -8 | -2.91173794359 | 274.75 | 339 | 259 | 17331 | 305.85434302 | DE |
156 | 43.75 | 19.6188340807 | 223 | 339 | 214.75 | 22321 | 260.0881129 | DE |
260 | 23.6 | 9.70594283364 | 243.15 | 339 | 185.26 | 15243 | 255.558447 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions